Mount Sinai Department of Medicine shared a post on LinkedIn:
“John Mascarenhas, MD, discusses his research on myelofibrosis – the first study to evaluate a combination therapy approach instead of a single treatment.
“We are hopeful this study will mark the beginning of a new era in myelofibrosis treatment,” said Dr. Mascarenhas. “Our findings highlight the potential of combination therapies to achieve deeper and more durable responses.”
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Authors: Raajit K. Rampal, John Mascarenhas et al.
